Merck KGaA

Merck KGaA

Sector: Pharmaceutical Preparations Region: Germany

: | OTC Markets: MKGAY | OTC Markets: MKGAF | XETRA: MRK | London Stock Exchange: 0O14

Similar to: Skystar Bio-Pharmaceutical Co., Shire PLC, United-Guardian, Inc.

Merck KGaA operates as a pharmaceutical, chemical and life science company, which engages in the research and development of innovative drugs and chemicals. The company operates through four divisions: Merck Serono, Consumer Health, Performance Materials & Merck Millipore. The Merck Serono division is biopharmaceutical division which markets both chemical and biotechnological products. The Consumer Health division is an over-the-counter drug business primarily focused on Europe (France, Germany and the U.K.), with a growing presence in Emerging Markets. The Performance Materials division engages in the chemicals business that offers high-tech performance chemicals for applications in fields such as consumer electronics, lighting, coatings, printing, plastics, and cosmetics. The Merck Millipore division involves in the life science tools businesses in the world and provides products used for laboratory research and the production of biologic drugs. Merck was founded in 1668 and is headquartered in Darmstadt, Germany.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Virtual guided tour through the Merck KGaA's new GMP Process Solution Plant.

Merck KGaA video

Virtual guided tour through the Merck KGaA's new GMP Process Solution Plant.

Merck KGaA video

Merck KGaA - Employee Video

Merck KGaA video

Investing in the future -- Merck KGaA is building a new inorganic salts product facility


Karl-Ludwig Kley, Chairman
Karl-Ludwig Kley was born on June 11, 1951 in Munich, Germany. After having completed an industrial business apprenticeship at Siemens AG, he studied law at Ludwig Maximilians University in Munich from 1974 to 1979. He completed his practical training as a lawyer in Hamburg, Germany, and Johannesburg, South Africa, from 1979 to 1982. He earned a doctorate in law (Dr. jur.) from the University of Munich in 1986 while working. Kley joined Bayer AG in 1982. Initially, he worked in Corporate Finance and later became the assistant to the Chairman of the Management Board. After serving as Chief Financial Officer in Japan, he held a number of senior executive positions within sales and marketing of the Pharmaceutical division from 1991 to 1994. He then served as Head of the Pharmaceutical division at the Italian subsidiary of Bayer until 1997. Subsequently, he was in charge of Corporate Finance and Investor Relations at Bayer headquarters. In 1998, Kley became a member of the Executive Board and Chief Financial Officer of Lufthansa AG. In September 2006, Karl-Ludwig Kley joined Merck KGaA in Darmstadt as Vice Chairman of the Executive Board. He was appointed Chairman of the Executive Board in late April 2007. Karl-Ludwig Kley is married and has one son. Responsibility for Group functions Group Strategy; Group Communications and Public Affairs; Group Legal & Compliance; Group Auditing External board positions
BMW AG, Vice Chairman of the Supervisory Board
Bertelsmann AG, Member of the Supervisory Board
German Chemical Industry Association (Verband der Chemischen Industrie e.V., VCI), Vice President
Baden-Badener Unternehmergespräche, Chairman of the Management Board
Federation of German Industry (Bundesverband der Deutschen Industrie e.V., BDI), Member of the Board
1. FC Köln GmbH & Co. KGaA, Chairman of the Supervisory Board
Goethe Institute, Member of the Business and Industry Advisory Board
WHU – Otto Beisheim School of Management, Honorary Professor
Matthias Zachert, Chief Financial Officer
Matthias Zachert was born on November 8, 1967 in Bonn, Germany. Following an industrial management apprenticeship at Mercedes-Benz AG, he studied business administration with a concentration in finance and international management from 1990 to 1995. He holds a degree in business administration (Diplom-Kaufmann). Following his studies, Zachert joined the former Hoechst AG. He held various senior management positions in the pharmaceutical business, including responsibility for the IPO project to spin of the subgroup Hoechst Marion Roussel (HMR). In the course of the combination of HMR and Rhône-Poulenc Rorer to form Aventis Pharma AG, Zachert became Chief Financial Officer of the International Region based in Paris, France. In 2002, Zachert transferred to Kamps AG as Chief Financial Officer. In this position, he contributed to the strategic repositioning of the company. Zachert was appointed Chief Financial Officer of Lanxess AG in 2004. At Lanxess, he was responsible for setting up the global finance organization as well as for the newly established company’s capital market communications. In addition, he played a key role in restructuring the portfolio and internationalizing Lanxess in recent years. Matthias Zachert was appointed Member of the Executive Board and Chief Financial Officer of Merck KGaA effective June 1, 2011. Matthias Zachert is married and has three children. Responsibility for Group functions Group Accounting; Group Controlling and Risk Management; Corporate Finance, M&A and Treasury; Group Taxes; Group Insurance; Group Procurement; Investor Relations External board positions
Institut für Unternehmungsplanung (IUP), Member of the Scientific Committee
German Financial Executives Institute (Gesellschaft für Finanzwirtschaft in der Unternehmensführung e.V., GEFIU), Member
Stefan Oschmann, Head of the Pharmaceuticals business sector
Dr. Stefan Oschmann was born on July 25, 1957 in Würzburg, Germany. After earning a degree in veterinary medicine and a doctorate at Ludwig-Maximilians University in Munich, he took on a position at the International Atomic Energy Agency IAEA. In 1989 he joined the American company Merck & Co. (outside North America: MSD – Merck Sharp & Dohme). Following various positions in Belgium, the Netherlands and Austria he was appointed Vice President of Central and Eastern Europe in 1998 and Vice President of Europe in 1999. Until 2005 Stefan Osch-mann was also in charge of the German business of Merck & Co. In 2005 he moved to the headquarters of Merck & Co., taking on the role of Senior Vice President in charge of Worldwide Human Health Marketing. In 2006 he became Member of Senior Management and Corporate Officer, in charge of Merck & Co.’s business in Europe, the Middle East, Africa and Canada. As of 2009, Stefan Oschmann served as President of Emerging Markets for Merck & Co. On January 1, 2011, Stefan Oschmann was appointed Member of the Executive Board of Merck KGaA. In this capacity, he is responsible for the Pharmaceuticals business sector. Stefan Oschmann is married and has two children. Responsibility for Group functions
Group Patents & Scientific Information
External board positions
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Vice President
European Federation of Pharmaceutical Industries and Associations (EFPIA), Member of the Board
German Association of Research-Based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller, vfa), Member of the Board
Paul Ehrlich-Stiftung, Member of the Board of Trustees

News & Analysis

You may also be interested in: